Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript
Orexo AB reported its Q1 2026 results, marking the first quarter without Zubsolv following its sale at the end of 2025. The transition was described as smooth, though it involved significant operational activity and impacted cash levels. Financial details were limited due to the absence of the former commercial asset. Management emphasized progress in streamlining operations post-divestiture.
- ▪Orexo AB completed the sale of Zubsolv on December 31, 2025, removing it from Q1 2026 financial reporting.
- ▪The company experienced a cash position reduction in Q1 2026 due to transition-related payments and operational adjustments.
- ▪SEK 52 million in cash on the balance sheet is attributable to Dexcel, related to accounts receivable management.
- ▪The Zubsolv transition was described as successful and operationally seamless by CEO Nikolaj Sørensen.
- ▪Executive VP & CFO Frederik Jarrsten reviewed the financial results during the earnings call.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895174-orexo-ab-publ-orxoy-q1-2026-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
